Hot Investor Mandate: VC With US & Europe Offices Invests Up to $15M in R&D Enabling Technologies, Considering Global Opportunities

11 Apr

A venture capital firm based in Europe with offices in the US traditionally invests in agtech but is also currently interested in the intersections between bioeconomy and traditional life sciences. The firm is currently investing out of its $400M fund in Seed to Series B companies with typical check sizes ranging from $1-15M USD. The firm is opportunistic in geography but has preference in the EU and US. The firm can act as a lead investor or syndicate. 
 
In terms of life sciences, the firm is interested in R&D enabling software, non-software enabling technologies, and medical foods whether that is asset- or software-oriented. 
 
The firm does not require to take a board seat and does not have specific management team requirements. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   
 

Leave a comment